A phase II study of laquinimod in Crohn's disease

OBJECTIVE: Laquinimod is an oral therapeutic agent under investigation for the treatment of Crohn's disease (CD), Huntington's disease, lupus nephritis and multiple sclerosis. This dose escalation study evaluated the safety and efficacy of laquinimod as induction therapy in patients with a...

Descripción completa

Detalles Bibliográficos
Autores principales: D'Haens, Geert, Sandborn, William J, Colombel, Jean Frederic, Rutgeerts, Paul, Brown, Kurt, Barkay, Hadas, Sakov, Anat, Haviv, Asi, Feagan, Brian G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515993/
https://www.ncbi.nlm.nih.gov/pubmed/25281416
http://dx.doi.org/10.1136/gutjnl-2014-307118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515993/
https://www.ncbi.nlm.nih.gov/pubmed/25281416
http://dx.doi.org/10.1136/gutjnl-2014-307118

Ejemplares similares